- Benign Prostatic Hyperplasia
- Hormone Therapy
- Genomic Testing
- Next-Generation Imaging
- UTUC
- OAB and Incontinence
- Genitourinary Cancers
- Kidney Cancer
- Men's Health
- Pediatrics
- Female Urology
- Sexual Dysfunction
- Kidney Stones
- Urologic Surgery
- Bladder Cancer
- Benign Conditions
- Prostate Cancer
Dr. Bradley Gill on key BPH research from AUA 2023
Bradley Gill, MD, MS, recaps several presentations on benign prostatic hyperplasia from the 2023 American Urological Association Annual Meeting in Chicago, Illinois.
In this video, Bradley Gill, MD, MS, recaps several presentations on benign prostatic hyperplasia from the 2023 American Urological Association Annual Meeting in Chicago, Illinois. Gill is an associate professor of urology at Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio.
The following research is discussed:
1. MP76-02 (Kaplan et al): At 4 years, Optilume BPH has the highest sustained improvement in peak flow (Qmax) of any minimally invasive BPH therapy
2. MP76-04 (Elterman): Prostate volume reduction by Rezum water vapour thermal therapy in glands <80 cc and >80 cc
3. MP76-07 (Lee et al): The impact of previous benign prostatic hypertrophy surgery on water ablation therapy: A comparison of safety and efficacy
4. Society of Benign Prostate Disease meeting highlights
